The Maharashtra Meals and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd’s Carry and Forwarding (C&F) facility at Wadki in Pune, citing critical irregularities discovered throughout inspections linked to Reactin Plus tablets.
The licences had been cancelled with impact from August 27, the FDA officers stated on Friday.
The motion was taken following an inspection of the corporate’s predominant warehouse in June. In the course of the inspection FDA officers discovered unauthorised promotional textual content on the packaging of Reactin Plus, a Schedule H prescription medication. The phrases “analgesic and antipyretic” had been discovered on the packaging, in line with the FDA.
Additionally learn: Bar on sale of loose oil in force since 2011, Mundhe clarifies
Medicines price ₹11.19 lakh seized
The regulator seized Reactin Plus inventory price ₹11.19 lakh and ordered the agency to recall the drug from the market, citing packaging violations as per the provisions of the Medicine and Cosmetics Act, 1940 and Guidelines, 1945.
The FDA stated such promotion of a prescription medication may encourage folks to take the drug with out medical recommendation, growing the danger of self-medication.
Additionally learn: HC orders fresh FDA check of Mumbai Cricket Association eateries amid licence suspension
Irregularities in storage, distribution
The next inspection of the corporate’s C&F operations additionally discovered a number of irregularities within the storage and distribution of medicines. These included discrepancies between bodily and computerised inventory data, gaps in buy and sale data, and non-compliance with recall instructions.
Additionally learn: Hry FDA dept conducts inspection at Gurugram restaurant after worm found in food
Moreover, inspectors additionally discovered medicines saved immediately on the ground and insufficient pallet and rack amenities. The FDA additional flagged shortcomings within the data and procedures for dealing with expired medicines.
Present-cause discover issued
The FDA had issued a show-cause discover to the corporate over the alleged violations. Its response was examined by the FDA earlier than the licences had been cancelled beneath the related provisions of the Medicine and Cosmetics Act and Medicine Guidelines.
FDA Commissioner Tukaram Mundhe stated the division wouldn’t compromise on drug security and public well being. “Strict compliance with authorized provisions is crucial, notably within the promoting, sale, storage and distribution of Schedule H prescription medicines. Any violation by any a part of the drug manufacturing or distribution system will invite strict motion beneath the regulation,” Mundhe stated.
